Decoy Therapeutics Inc.
Data quality: 83%
DCOY
Nasdaq
Manufacturing
Chemicals
$6.00
▲
$0.37
(6.57%)
Mkt Cap: 3.19 M
Price
$6.00
Mkt Cap
3.19 M
Day Range
$5.63 — $6.05
52-Week Range
$5.40 — $415.80
Volume
13,340
Open $5.80
50D / 200D Avg
$8.14
26.27% below
50D / 200D Avg
$48.08
87.52% below
Quick Summary
Key Takeaways
Negative free cash flow of -4.83 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-732.43%
Below sector avg (-53.41%)
ROIC-266.10%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Valuation
PE (TTM)
-0.25
Above sector avg (-1.48)
P/B Ratio0.75
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.3 | -1.5 |
| P/B | 0.8 | 1.6 |
| ROE % | -732.4 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -12.52 M |
| ROE | -732.43% | ROA | -334.28% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -4.83 M |
| ROIC | -266.10% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 4.25 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.25 | Forward P/E | N/A |
| P/B Ratio | 0.75 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -151.22% | ||
| Market Cap | 3.19 M | Enterprise Value | -1.62 M |
| Per Share | |||
| EPS (Diluted TTM) | -129.10 | Revenue / Share | N/A |
| FCF / Share | -9.07 | OCF / Share | -9.07 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 38.56% |
| SBC-Adj. FCF | -4.97 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 0.0 | 1.84 M |
| Net Income | -12.52 M | -5.58 M | -12.54 M | -31.61 M | -12.77 M |
| EPS (Diluted) | -129.10 | -5.79 | -3.84 | -14.88 | -0.31 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -12.61 M | -5.73 M | -12.89 M | -31.84 M | -12.81 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 368,170.0 | 770,027.0 | 7.17 M | 15.84 M | 8.55 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 7,151.0 | 4,424.0 | 10,051.0 | 6,677.0 | 19,183.0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 11.06 M | 3.02 M | 6.59 M | 14.65 M | 40.83 M |
| Total Liabilities | 5.17 M | 1.51 M | 1.30 M | 4.27 M | 2.11 M |
| Shareholders' Equity | 5.89 M | 1.51 M | 5.29 M | 10.38 M | 38.72 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 10.71 M | 2.43 M | 5.90 M | 12.11 M | 29.21 M |
| Current Assets | 10.99 M | 2.99 M | 6.52 M | 14.52 M | 30.16 M |
| Current Liabilities | 5.17 M | — | — | — | — |
{"event":"ticker_viewed","properties":{"ticker":"DCOY","listing_kind":"stock","pathname":"/stocks/dcoy","exchange":"Nasdaq","country":"US"}}